company background image
RNO

RhinomedASX:RNO Stock Report

Market Cap

AU$79.9m

7D

5.0%

1Y

80.0%

Updated

18 Oct, 2021

Data

Company Financials
RNO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

RNO Overview

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for Rhinomed
Historical stock prices
Current Share PriceAU$0.32
52 Week HighAU$0.10
52 Week LowAU$0.48
Beta0.68
1 Month Change-10.00%
3 Month Change57.50%
1 Year Change80.00%
3 Year Change28.57%
5 Year Change57.50%
Change since IPO-95.33%

Recent News & Updates

Jul 09
Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Rhinomed...

Mar 01
Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

RNOAU PharmaceuticalsAU Market
7D5.0%0.04%0.9%
1Y80.0%-2.4%20.2%

Return vs Industry: RNO exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: RNO exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is RNO's price volatile compared to industry and market?
RNO volatility
RNO Beta0.68
Industry Beta1.3
Market Beta1

Stable Share Price: RNO is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 32% a week.

Volatility Over Time: RNO's weekly volatility has increased from 20% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004n/aMichael Johnsonhttps://www.rhinomed.global

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company’s product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab.

Rhinomed Fundamentals Summary

How do Rhinomed's earnings and revenue compare to its market cap?
RNO fundamental statistics
Market CapAU$79.95m
Earnings (TTM)-AU$8.64m
Revenue (TTM)AU$4.42m

18.1x

P/S Ratio

-9.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RNO income statement (TTM)
RevenueAU$4.42m
Cost of RevenueAU$1.14m
Gross ProfitAU$3.28m
ExpensesAU$11.92m
Earnings-AU$8.64m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.034
Gross Margin74.16%
Net Profit Margin-195.40%
Debt/Equity Ratio0%

How did RNO perform over the long term?

See historical performance and comparison

Valuation

Is Rhinomed undervalued compared to its fair value and its price relative to the market?

16.79x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RNO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RNO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RNO is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: RNO is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RNO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RNO is overvalued based on its PB Ratio (16.8x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is Rhinomed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rhinomed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Rhinomed performed over the past 5 years?

-13.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RNO is currently unprofitable.

Growing Profit Margin: RNO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RNO is unprofitable, and losses have increased over the past 5 years at a rate of 13.3% per year.

Accelerating Growth: Unable to compare RNO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RNO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: RNO has a negative Return on Equity (-181.34%), as it is currently unprofitable.


Financial Health

How is Rhinomed's financial position?


Financial Position Analysis

Short Term Liabilities: RNO's short term assets (A$3.8M) exceed its short term liabilities (A$1.4M).

Long Term Liabilities: RNO's short term assets (A$3.8M) exceed its long term liabilities (A$400.7K).


Debt to Equity History and Analysis

Debt Level: RNO is debt free.

Reducing Debt: RNO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RNO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RNO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.4% each year


Dividend

What is Rhinomed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RNO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RNO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RNO's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average board tenure


CEO

Michael Johnson

8.67yrs

Tenure

AU$2,201,200

Compensation

Mr. Michael Johnson serves as the Chief Executive Officer, Managing Director and Executive Director of Rhinomed Limited (formerly, Consegna Group Limited) since February 1, 2013. Mr. Johnson serves as a Di...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD1.63M) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: RNO's board of directors are considered experienced (7.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Rhinomed Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Rhinomed Limited
  • Ticker: RNO
  • Exchange: ASX
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$79.950m
  • Shares outstanding: 253.81m
  • Website: https://www.rhinomed.global

Location

  • Rhinomed Limited
  • 132 Gwynne Street
  • Level 1
  • Cremorne
  • Victoria
  • 3121
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:28
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.